American Society of Hirudotherapy

Heparin versus bivalirudin for anticoagulation in adult extracorporeal membrane oxygenation: a systematic review and meta-analysis

Systematic review and meta-analysis published in ASAIO Journal (2023)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Meta-analysisClinical TrialsDrug DevelopmentWieruszewski PM et al. · ASAIO journal, 2023

Abstract

Extracorporeal membrane oxygenation (ECMO) poses unique thrombotic and hemorrhagic risks, and the optimal anticoagulant choice is unknown. We systematically searched Ovid EBM Reviews, Ovid Embase, Ovid Medline, Scopus, and Web of Science Core Collection for randomized-, crossover-, retrospective cohort-, or parallel-designed clinical studies of adult patients receiving ECMO that compared heparin recipients with bivalirudin recipients. Meta-analysis was performed with random-effects models. The ROBINS-I tool was used to assess the risk of bias. Six retrospective observational studies met the inclusion criteria for the qualitative summary. Five studies were suitable for meta-analysis. Those who received heparin were more likely to experience circuit-related thrombosis (odds ratio [OR] 2.05, 95% confidence interval [CI] 1.25-3.37, p = 0.005, I2 = 0%) and die (OR 1.62, 95% CI 1.19-2.21, p = 0.002, I2 = 0%) compared with those who received bivalirudin. There were no differences in major bleeding events between heparin and bivalirudin recipients (OR 1.83, 95% CI 0.55-6.09, p = 0.33, I2 = 82.7%). In retrospective settings compared with heparin anticoagulation, bivalirudin was associated with less circuit-related thrombotic events and greater survival in adults supported on ECMO, without contributing to more bleeding complications. Prospective controlled studies comparing heparin and bivalirudin in adult ECMO patients are warranted to corroborate these findings.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeMeta-AnalysisSystematic ReviewJournal Article
Indexed MeSH termsAdultHumansAnticoagulantsExtracorporeal Membrane OxygenationHeparinHirudinsPeptide FragmentsProspective StudiesRecombinant ProteinsRetrospective StudiesThrombosisHirudin Therapy

Summary

Meta-analysis of bivalirudin vs heparin in adult ECMO. Bivalirudin associated with fewer thromboses, similar bleeding, and improved time within target aPTT range.

Why This Matters for Hirudotherapy

This systematic review and meta-analysis compared heparin versus bivalirudin anticoagulation in adult patients receiving extracorporeal membrane oxygenation, pooling data from six retrospective observational studies (five suitable for meta-analysis). Patients receiving heparin were significantly more likely to experience circuit-related thrombosis and death compared to bivalirudin recipients, with no significant difference in major bleeding events between groups. The abstract does not discuss leeches, hirudin derivation, or hirudotherapy, so no defensible connection to ASH's domain can be established from this article alone. The evidence base is entirely retrospective and observational, and the study involves a pharmaceutical anticoagulant in critical care rather than leech therapy.

Citation

Heparin versus bivalirudin for anticoagulation in adult extracorporeal membrane oxygenation: a systematic review and meta-analysis.

Wieruszewski PM et al. · ASAIO journal, 2023

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.